# Intravenously Administered M6229 in Critically Ill Sepsis Patients

> **NCT05208112** · PHASE1 · COMPLETED · sponsor: **A.P.J. Vlaar** · enrollment: 10 (actual)

## Conditions studied

- Sepsis
- Septic Shock
- Critical Illness

## Interventions

- **DRUG:** M6229

## Key facts

- **NCT ID:** NCT05208112
- **Lead sponsor:** A.P.J. Vlaar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-05
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208112, "Intravenously Administered M6229 in Critically Ill Sepsis Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05208112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*